Clinical Trials Logo

Filter by:
  • Suspended  
  • Page [1]
NCT ID: NCT05935332 Suspended - Asthma Clinical Trials

Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

Start date: July 5, 2023
Phase: Phase 2
Study type: Interventional

Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled corticosteroids (ICS) in combination with long-acting beta 2 agonist (LABA).

NCT ID: NCT05261139 Suspended - COVID-19 Clinical Trials

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

Start date: March 7, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this clinical trial is to learn about the safety, pharmacokinetics (pharmacokinetics helps us understand how the drug is changed and eliminated from your body after you take it), and efficacy (how well a study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID-19). The study medicine will be given to patients under 18 years of age with COVID-19 that are not hospitalized but are at risk for severe disease.

NCT ID: NCT05178862 Suspended - Candidemia Clinical Trials

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

MARIO
Start date: August 3, 2022
Phase: Phase 3
Study type: Interventional

This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis included candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous echinocandin followed by oral fluconazole.

NCT ID: NCT04854512 Suspended - Clinical trials for Diabetes Mellitus, Type 2

Investigational Study of Delayed Release Metformin

DREAM-T2D
Start date: May 18, 2021
Phase: Phase 3
Study type: Interventional

In Phase 1 and 2 studies already conducted, Metformin DR, with its targeted delivery to the distal small intestine, has shown the potential to be a safe and effective way to improve glycemic control in patients with T2DM and CKD with less systemic metformin exposure. The primary purpose of this Phase 3 clinical study is to collect pivotal data confirming the safety and efficacy of Metformin DR in T2DM patients with varying renal function from normal up to CKD3B.